KAI1/CD82与C-erbB-2在乳腺癌中的表达及其临床意义

    Expression of KAI1/CD82 and C-erbB-2 in breast cancer and its clinical significance

    • 摘要: 目的: 探讨KAI1/CD82及C-erbB-2在乳腺癌中的表达及其临床意义。方法: 采用免疫组织化学S-P法检测57例乳腺癌组织和11例乳腺良性病变组织中KAI1/CD82及C-erbB-2的表达,分析其与临床病理参数的关系。结果: 57例乳腺癌组织和11例乳腺良性病变组织中KAI1/CD82、C-erbB-2阳性率分别为31.58%和81.82%、71.93%和0.00%,差异均有统计学意义(P < 0.01)。乳腺癌患者中,淋巴结未转移、雌激素受体(ER)阴性者的KAI1/CD82阳性率高于淋巴结转移、ER阳性者(P <0.05);ER阳性患者C-erbB-2的阳性率低于ER阴性者(P < 0.05)。KAI1/CD82与C-erbB-2在乳腺癌中的表达无相关关系(P >0.05)。结论: KAI1/CD82和C-erbB-2均参与了乳腺癌的发生、发展过程,对乳腺癌的浸润和转移及预后评估具有临床参考意义。

       

      Abstract: Objective: To explore the expression of KAI1/CD82 and C-erbB-2 in breast cancer and its clinieal significance. Methods: The expression of KAI1/CD82,C-erbB-2 and estrogen receptor (ER) in 57 cases of breast cancer and 11 cases of benign mammary lesions were detected by immunohistochemistry S-P method,and their correlation with the clinicopathologic features was analyzed. Results: The positive rate of KAI1/CD82 was 31.58% in the breast cancer and 81.82% in the benign mammary lesions. The positive rate of C-erbB-2 was 71.93% in the breast cancer and zero in benign mammary lesions. The difference was statistically significant between the two groups (P < 0.01). The positive expression of KAI1/CD82 had statistical difference in cases with no metastasis of auxiliary lymph nodes and cases with negative expression of ER (P < 0.05). The positive expression of C-erbB-2 in cases with positive expression of ER was lower than that in cases with negative expression of ER (P < 0.05). The expression of KAI1/CD82 and C-erbB-2 in breast cancer had no correlation. Conclusions: KAI1/CD82 and C-erbB-2 both participate in the proceeding of breast cancer,they may help to evaluate the invasiveness and metastasis of breast cancer.

       

    /

    返回文章
    返回